کد مقاله | کد نشریه | سال انتشار | مقاله انگلیسی | نسخه تمام متن |
---|---|---|---|---|
10964725 | 1102725 | 2014 | 9 صفحه PDF | دانلود رایگان |
عنوان انگلیسی مقاله ISI
Aluminium in allergen-specific subcutaneous immunotherapy - A German perspective
ترجمه فارسی عنوان
آلومینیوم در ایمنوتراپی زیر جلدی خاص آلرژیک - چشم انداز آلمانی
دانلود مقاله + سفارش ترجمه
دانلود مقاله ISI انگلیسی
رایگان برای ایرانیان
کلمات کلیدی
PEICHMPEMATWIEFSAMPLSCITdFG - DFGAluminium - آلومینیومEuropean Medicine Agency - آژانس پزشکی اروپاSafety - ایمنیimmunotherapy - ایمونوتراپیsubcutaneous immunotherapy - ایمونوتراپی زیر جلدیWorld Health Organisation - سازمان بهداشت جهانیToxicity - سمی بودنMonophosphoryl lipid A - لیپید مونوفسفریل ATolerable weekly intake - مصرف هفتگی قابل تحملWHO - که
موضوعات مرتبط
علوم زیستی و بیوفناوری
ایمنی شناسی و میکروب شناسی
ایمونولوژی
چکیده انگلیسی
However, allergen-specific immunotherapy commonly consists of administering a long-course programme of subcutaneous injections using preparations of relevant allergens. Regulatory authorities currently set aluminium limits for vaccines per dose, rather than per treatment course. Unlike prophylactic vaccinations, numerous injections with higher proportions of aluminium-adjuvant per injection are applied in subcutaneous immunotherapy (SCIT) and will significantly contribute to a higher cumulative life dose of aluminium. While the human body may cope robustly with a daily aluminium overload from the environment, regulatory cumulative threshold values in immunotherapy need further addressing. Based on the current literature, predisposing an individual to an unusually high level of aluminium, such as through subcutaneous immunotherapy, has the potential to form focal accumulations in the body with the propensity to exert forms of toxicity. Particularly in relation to longer-term health effects, the safety of aluminium adjuvants in immunotherapy remains unchallenged by health authorities - evoking the need for more consideration, guidance, and transparency on what is known and not known about its safety in long-course therapy and what measures can be taken to prevent or minimise its risks. The possibility of providing an effective means of measuring aluminium accumulation in patients undergoing long-term SCIT treatment as well as reducing their aluminium body burden is discussed.
ناشر
Database: Elsevier - ScienceDirect (ساینس دایرکت)
Journal: Vaccine - Volume 32, Issue 33, 16 July 2014, Pages 4140-4148
Journal: Vaccine - Volume 32, Issue 33, 16 July 2014, Pages 4140-4148
نویسندگان
Matthias F. Kramer, Matthew D. Heath,